Clinical Research Papers:
The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion
Metrics: PDF 2085 views | HTML 2244 views | ?
Abstract
Qing-Kun Song1,*, Jun Ren1,2,3,*, Xin-Na Zhou1,2, Xiao-Li Wang1,2, Guo-Hong Song2, Li-Jun Di2, Jing Yu2, Amy Hobeika3, Michael A. Morse4, Yan-Hua Yuan1, Hua-Bing Yang1, Herbert Kim Lyerly3
1Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China
2Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
3Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States
4Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
*These authors have contributed equally to this work
Correspondence to:
Jun Ren, e-mail: [email protected]
Herbert Kim Lyerly, e-mail: [email protected]
Keywords: CD4+CD25+ T lymphocyte, early stage breast cancer, triple negative breast cancer, prognosis, adoptive cell therapy
Received: June 16, 2015 Accepted: September 07, 2015 Published: October 05, 2015
ABSTRACT
Objective: This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.
Methods: 217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.
Results: Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.
Conclusion: Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5534